Business Wire

Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States

Jaa

Gilead Sciences, Inc. (NASDAQ:GILD) today announced the launch of the Gilead COMPASS ( COM mitment to P artnership in A ddressing HIV/AIDS in S outhern S tates) Initiative, a 10-year, $100 million commitment to support organizations working to address the HIV/AIDS epidemic in the Southern United States. Gilead will partner with three coordinating centers to lead the corporate giving program of the initiative: Emory University Rollins School of Public Health, the University of Houston Graduate College of Social Work and the Southern AIDS Coalition. These coordinating centers will identify and provide funding to local organizations that are committed to addressing the epidemic throughout the region, focusing on capacity building and shared knowledge; wellbeing, mental health and trauma-informed care; and awareness, education and anti-stigma campaigns.

“HIV/AIDS remains an urgent public health crisis in the United States and this is particularly apparent in the Southern states where rates of new infection rival those seen in the 1980s. In some communities, those rates are actually rising – a chilling reminder that the epidemic is far from a thing of the past,” said Gregg Alton, Executive Vice President, Corporate and Medical Affairs, Gilead Sciences. “We recognize a collaborative effort is needed and we are very pleased to partner with local organizations that are uniquely positioned to address the epidemic on the ground.”

According to the Centers for Disease Control and Prevention (CDC), the Southern United States accounts for approximately 45 percent of all people living with an HIV diagnosis in the country, despite being home to only one third of the population.1,2 Nearly half of all people dying from HIV/AIDS in the United States live in a Southern state.3 HIV disproportionally affects Latinos; transgender women; Black women; and Black gay and bisexual men, in part due to stigma, poverty, lack of access to healthcare and racial inequality.4 Of all Black gay and bisexual men who were diagnosed with HIV in the United States in 2014, more than 60 percent live in a Southern state.

“Limited access to healthcare and information about life-saving advances in HIV treatment and prevention in the most vulnerable communities creates an environment where we, as a society, have the tools in hand to improve lives, but these resources are not being fully utilized to address the epidemic,” said Dr. Charlene Flash, Assistant Professor of Medicine, Division of Infectious Diseases, Baylor College of Medicine. “We must take action and apply these resources to overcome this challenge as too many vulnerable people in the South cannot access, or worse still, are unaware of the existing life-saving tools to prevent and treat HIV.”

About the Gilead COMPASS Initiative

The Gilead COMPASS Initiative is a $100 million commitment over 10 years in the Southern United States supporting organizations working to address the HIV/AIDS epidemic. The corporate giving program of the initiative has a threefold mission: to build capacity and increase knowledge sharing among community-based, underfunded organizations in Southern states; to explore interventions that appropriately respond to patients’ needs, including the bundling or reframing of mental health care, as well as the intersection between substance use, the opioid epidemic and HIV/AIDS; and to fund awareness and anti-stigma campaigns. Through this initiative, Gilead plans to dramatically increase the reach of these organizations working to address the epidemic in the region, and ultimately to improve the lives of those affected by HIV/AIDS.

About Gilead’s Commitment in HIV

For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care and cure research. In further efforts to end the HIV/AIDS epidemic, Gilead is conducting early-stage clinical research to identify novel agents and strategies that could play a role in eradicating HIV infection in the body.

Gilead’s corporate giving program aims to reduce disparities, provide access, advance education and support local communities. In 2016, Funders Concerned About AIDS (FCAA) recognized Gilead as the leading corporate global funder of HIV/AIDS programs, and second overall behind the Bill & Melinda Gates Foundation.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter ( @GileadSciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

1 CDC. HIV in the United States by Geographic Distribution. Available at: https://www.cdc.gov/hiv/statistics/overview/geographicdistribution.html. Accessed: November 11, 2017.

2 United States Census Bureau. Annual Estimate of the Resident Population: April 1, 2010 to July 1, 2015. Available at: https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=PEP_2014_PEPANNRES&src=pt. Accessed: November 14, 2017.

3 CDC. HIV in the Southern United States. Available at: https://www.cdc.gov/hiv/pdf/policies/cdc-hiv-in-the-south-issue-brief.pdf. Accessed: November 13, 2017.

4 Valdiserri RO. HIV/AIDS Stigma: An Impediment to Public Health. Am J Public Health. 2002;92(3):341–34.

Quotes from Coordinating Centers

Emory University, Rollins School of Public Health: Capacity building and shared knowledge.

“Community-based organizations faced with diminishing long-term financial resources and increased community needs are challenged to ‘do more with less,’” said Candace Meadows, Project Director, Emory COMPASS Coordinating Center. “The Emory center will support organizations to enhance organizational capacity, operational efficiencies and their ability to secure resources that positively impact communities with greatest need.”

The University of Houston Graduate College of Social Work: Wellbeing, mental health and trauma-informed care.

“We’re grateful for this opportunity to fight such an important, yet challenging, fight,” said Samira Ali, Project Director and Assistant Professor, University of Houston Graduate College of Social Work. “As part of the Gilead COMPASS Initiative, the University of Houston is committed to addressing HIV/AIDS disparities. By using a community-centered approach, we’ll mobilize people to be part of the solution.”

The Southern AIDS Coalition: Awareness, education and anti-stigma campaigns.

“We can end the HIV epidemic in the Southern United States,” said Nicholas Carlisle, Executive Director, Southern AIDS Coalition. “To do so will require broad, cross-sector collaboration where all stakeholders coordinate efforts, share best practices and leverage scarce resources in innovative and unprecedented ways.”

Contact information

Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Brent Tippen, 650-653-9354

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar16.12.2017 01:13Tiedote

Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 15:34Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712

Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 15:21Tiedote

Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr

Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 14:38Tiedote

A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L

Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 14:00Tiedote

Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a

AML BitCoin Enters Phase II of ICO15.12.2017 12:00Tiedote

NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme